Biogen: Phase 2 BIIB059 Study Meets Primary Endpoints in Lupus
04 December 2019 - 12:15AM
Dow Jones News
By Colin Kellaher
Biogen Inc. (BIIB) on Tuesday said a Phase 2 study of its
BIIB059 antibody in patients with the autoimmune disease lupus met
its primary endpoints, showing statistically significant reduction
of disease activity compared to placebo.
The Cambridge, Mass., biopharmaceutical company said the
two-part study evaluated BIIB059 in individuals with active
cutaneous lupus erythematosus, including chronic and subacute
subtypes, with or without systemic manifestations, and in
individuals with systemic lupus erythematosus with active joint and
skin manifestations.
Biogen said the safety and tolerability profile of BIIB059
supports its continued development, adding that the study results
support the company's goal of building a multi-franchise
portfolio.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 03, 2019 08:00 ET (13:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Mar 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2023 to Mar 2024